Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 2.39
NEPT's Cash to Debt is ranked higher than
62% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. NEPT: 2.39 )
NEPT' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 2.39

Equity to Asset 0.61
NEPT's Equity to Asset is ranked higher than
70% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. NEPT: 0.61 )
NEPT' s 10-Year Equity to Asset Range
Min: -0.42   Max: 0.83
Current: 0.61

-0.42
0.83
F-Score: 1
Z-Score: 1.23
M-Score: -3.98
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -202.37
NEPT's Operating margin (%) is ranked higher than
67% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. NEPT: -202.37 )
NEPT' s 10-Year Operating margin (%) Range
Min: -116.18   Max: -9.17
Current: -202.37

-116.18
-9.17
Net-margin (%) -126.71
NEPT's Net-margin (%) is ranked higher than
70% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. NEPT: -126.71 )
NEPT' s 10-Year Net-margin (%) Range
Min: -156.23   Max: -10.08
Current: -126.71

-156.23
-10.08
ROE (%) -30.42
NEPT's ROE (%) is ranked higher than
74% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. NEPT: -30.42 )
NEPT' s 10-Year ROE (%) Range
Min: -596.63   Max: -9.66
Current: -30.42

-596.63
-9.66
ROA (%) -17.78
NEPT's ROA (%) is ranked higher than
77% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. NEPT: -17.78 )
NEPT' s 10-Year ROA (%) Range
Min: -82.24   Max: -5.71
Current: -17.78

-82.24
-5.71
ROC (Joel Greenblatt) (%) -54.11
NEPT's ROC (Joel Greenblatt) (%) is ranked higher than
82% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. NEPT: -54.11 )
NEPT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1925.98   Max: -12.44
Current: -54.11

-1925.98
-12.44
Revenue Growth (3Y)(%) -7.90
NEPT's Revenue Growth (3Y)(%) is ranked higher than
73% of the 721 Companies
in the Global Biotechnology industry.

( Industry Median: 0.40 vs. NEPT: -7.90 )
NEPT' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 32
Current: -7.9

0
32
EBITDA Growth (3Y)(%) 230.20
NEPT's EBITDA Growth (3Y)(%) is ranked higher than
100% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -5.00 vs. NEPT: 230.20 )
NEPT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 230.2
Current: 230.2

0
230.2
EPS Growth (3Y)(%) 89.00
NEPT's EPS Growth (3Y)(%) is ranked higher than
99% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: -9.10 vs. NEPT: 89.00 )
NEPT' s 10-Year EPS Growth (3Y)(%) Range
Min: -47.7   Max: 97.9
Current: 89

-47.7
97.9
» NEPT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

NEPT Guru Trades in Q1 2014

Jim Simons 20,200 sh (New)
» More
Q2 2014

NEPT Guru Trades in Q2 2014

Jim Simons 40,900 sh (+102.48%)
» More
Q3 2014

NEPT Guru Trades in Q3 2014

Jim Simons 42,300 sh (+3.42%)
» More
Q4 2014

NEPT Guru Trades in Q4 2014

Jim Simons 53,800 sh (+27.19%)
» More
» Details

Insider Trades

Latest Guru Trades with NEPT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 70.42
NEPT's Forward P/E is ranked higher than
87% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NEPT: 70.42 )
N/A
P/B 2.42
NEPT's P/B is ranked higher than
89% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 6.46 vs. NEPT: 2.42 )
NEPT' s 10-Year P/B Range
Min: 1.94   Max: 40.88
Current: 2.42

1.94
40.88
P/S 10.24
NEPT's P/S is ranked higher than
77% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. NEPT: 10.24 )
NEPT' s 10-Year P/S Range
Min: 0.91   Max: 33.87
Current: 10.24

0.91
33.87
Current Ratio 5.55
NEPT's Current Ratio is ranked higher than
77% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. NEPT: 5.55 )
NEPT' s 10-Year Current Ratio Range
Min: 0.4   Max: 5.93
Current: 5.55

0.4
5.93
Quick Ratio 3.93
NEPT's Quick Ratio is ranked higher than
73% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. NEPT: 3.93 )
NEPT' s 10-Year Quick Ratio Range
Min: 0.2   Max: 4.87
Current: 3.93

0.2
4.87
Days Inventory 343.83
NEPT's Days Inventory is ranked higher than
78% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. NEPT: 343.83 )
NEPT' s 10-Year Days Inventory Range
Min: 58.23   Max: 272.09
Current: 343.83

58.23
272.09
Days Sales Outstanding 192.11
NEPT's Days Sales Outstanding is ranked higher than
69% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. NEPT: 192.11 )
NEPT' s 10-Year Days Sales Outstanding Range
Min: 77.93   Max: 159.39
Current: 192.11

77.93
159.39

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 9.35
NEPT's Price/Net Current Asset Value is ranked higher than
78% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 28.08 vs. NEPT: 9.35 )
NEPT' s 10-Year Price/Net Current Asset Value Range
Min: 4.17   Max: 84.63
Current: 9.35

4.17
84.63
Price/Tangible Book 2.47
NEPT's Price/Tangible Book is ranked higher than
91% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 9.40 vs. NEPT: 2.47 )
NEPT' s 10-Year Price/Tangible Book Range
Min: 2.38   Max: 40.71
Current: 2.47

2.38
40.71
Price/Median PS Value 1.26
NEPT's Price/Median PS Value is ranked higher than
82% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 2.90 vs. NEPT: 1.26 )
NEPT' s 10-Year Price/Median PS Value Range
Min: 0.12   Max: 9
Current: 1.26

0.12
9
Earnings Yield (Greenblatt) -18.10
NEPT's Earnings Yield (Greenblatt) is ranked higher than
52% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. NEPT: -18.10 )
NEPT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 1.1
Current: -18.1

0.1
1.1

Analyst Estimate

Feb15 Feb16 Feb17 Feb18
EPS($) -0.22 0.02 0.14 0.18
EPS without NRI($) -0.22 0.02 0.14 0.18

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NTB.Canada, NTU.Germany,
Neptune Technologies & Bioressources Inc was incorporated on October 9, 1998. It is a biotechnology company engaged in the development, manufacture and commercialization of marine derived omega polyunsaturated fatty acids. It is engaged in the research, development and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries. The Company has three segments structured in three distinctive legal entities: the first is producing and commercializing nutraceutical products (Neptune); development and commercialization of pharmaceutical products for cardiovascular diseases applications (Acasti); and development and commercialization of pharmaceutical products for neurological diseases applications (NeuroBioPharm). The Company produces omega 3 PUFAs through its patented process of extracting oils from Antartic krill, which omega 3 PUFAs are then sold as bulk oil to company's distributors who commercialize them under their private label in the U.S., European and Australian nutraceutical markets. Its products include Neptune Krill Oil and ECOKRILL Oil generally come in capsule form and serves as a dietary supplement to consumers.
» More Articles for NEPT

Headlines

Articles On GuruFocus.com
What Drives St. Jude Medical to Be More Diversified? Apr 30 2014 

More From Other Websites
Neptune to Present at 27th Annual Roth Conference Mar 29 2015
USPTO Issues Positive Decision that Triggers Royalty Payments to Neptune Mar 29 2015
Acasti Granted Composition & Use Patent in China Mar 25 2015
USPTO Issues Positive Decision That Triggers Royalty Payments to Neptune Mar 23 2015
Why Neptune Technologies & Bioressources, Inc. (NEPT) Could Shock the Market Soon - Tale of the Tape Mar 03 2015
Neptune to Present at 27th Annual Roth Conference Mar 02 2015
Acasti Receives Full Data for Phase II TRIFECTA Trial Mar 02 2015
NeuroBioPharm Receives Final Court Approval and Completes Arrangement With Neptune Feb 20 2015
Why Neptune Technologies & Bioressources (NEPT) Could Be Positioned for a Surge? - Tale of the Tape Feb 18 2015
NeuroBioPharm's Shareholders Approve Arrangement With Neptune Feb 12 2015
Should Neptune Technologies & Bioressources (NEPT) Be On Your Radar Now? - Tale of the Tape Feb 10 2015
Dr. Tina Sampalis Appointed Medical Science Liaison for Neptune Feb 05 2015
Jim Hamilton Officially Starts at Neptune Feb 03 2015
Acasti Announces Third Quarter Results Jan 13 2015
Neptune Announces Third Quarter Results Jan 13 2015
NeuroBioPharm to be Privatized by Neptune - Enters Into Arrangement Agreement With Neptune and... Jan 13 2015
5 Earnings Short-Squeeze Plays: Neptune Technologies and More Jan 13 2015
Neptune to Present at OneMedForum Jan 08 2015
Neptune to Hold Conference Call to Discuss Third Quarter Results Jan 06 2015
Neptune Completes Plant Ramp-Up Dec 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK